Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Pfizer

Pfizer/BioNTech's COVID- Vaccine Cuts Hospitalization Risk In Kids Aged 5-11 Years: Reuters

According to a US-based study, children ages 5 to 11 who received the Pfizer Inc (NYSE:PFE) / BioNTech SE's (NASDAQ:BNTX) COVID-19 vaccine were 68% less likely to be hospitalized during the omicron wave than unvaccinated children. Adolescents aged 12-18 who received two shots of the vaccine were around 40% less likely to be hospitalized with the…

Benzinga

Opinion: In Crisis Mode, Shanghai Should Stick to Zero-Covid Approach

A UCLA professor’s long-term coexistence plan won’t help and could hinder Shanghai’s response to the current crisis, a Zhejiang University professor argues

Caixin Global

How This Top CEO Helped Pfizer Turbocharge The Covid-19 Vaccine

When Covid-19 stalled the world's economic motor in early 2020, ICON CEO Steve Cutler and his team at the vaccine trials company revved up.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Governments want COVID vaccine developers to aim higher in hunt for better shots

As governments prepare to live with COVID-19, some are questioning how much to rely on drugmakers to adapt vaccines to ward off future virus variants amid signs of tension between companies and regulators over the best approach, according to several sources familiar with the matter.

Reuters

Biden's looming prescription drug pricing dilemma

Pressure is increasing on the administration to go after drug patents.

Axios

FDA approves second shot for 50+

The authorization for another booster arrives just as BA.2 becomes the dominant strain in the U.S.

Salon

Opinion: How Shanghai Can Pioneer a New Path for Disease Control

Amid worst Covid-19 outbreak, city could turn pandemic into manageable endemic disease using self-isolation, self-testing and advanced drugs and vaccines

Caixin Global

Read news from The Economist, FT, and more,
with one subscription

Who really needs a second COVID booster? Here's what to know

Many Americans can now get a second COVID-19 booster, but it’s hard to tell who really needs another shot right now and who could wait

The Independent UK

Why BioNTech Shares Are Surging Today

BioNTech SE (NASDAQ:BNTX) reported Q4 FY21 revenues of €5.53 billion compared to €345.4 million a year ago, mainly due to high demand for the company's COVID-19 vaccine. BioNTech and its partner Pfizer Inc (NYSE:PFE) delivered approximately 2.6 billion doses of Comirnaty/BNT162b2 worldwide in 2021, including over 1 billion doses to low- and middle-income countries. As…

Benzinga

COVID-19 vaccines for the youngest children may be inching closer to authorization – a pediatrician explains how they're being tested

For some parents of young children, the wait for COVID-19 vaccines has been long and agonizing.

The Conversation

BioNTech's quarterly profit soars on COVID-19 vaccine demand

BioNTech has reported another quarter of strong earnings growth

The Independent UK

Commentary: There is much we still don’t know about giving 5- to 11-year-olds a COVID-19 vaccine

Should children ages 5 to 11 receive the COVID-19 vaccine? This is a difficult question without an easy answer, something you wouldn’t know from the strident opinions of politicians and health experts.

Chicago Tribune

FDA clears way for millions to get additional COVID-19 boosters

WASHINGTON — U.S. regulators cleared second booster doses of COVID-19 vaccine from Moderna Inc. and the partnership of Pfizer Inc. and BioNTech SE for adults 50 and older, making millions more people eligible for the shots as concern grows about a potential new wave of infections.

Tribune News Service

Infectious omicron BA.2 now dominant in US, with coronavirus spring rise likely

LOS ANGELES — The highly infectious BA.2 omicron subvariant is now the dominant version of the coronavirus circulating in the United States, according to federal estimates, a development that is triggering fresh concerns of a potential springtime wave.

Los Angeles Times

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

FDA Approves ViiV Healthcare's Cabenuva For Virologically Suppressed Adolescents With HIV

The FDA has approved ViiV Healthcare's Cabenuva (cabotegravir, rilpivirine) for HIV-1 in virologically suppressed adolescents. The approval covers patients aged 12 years or older and weighing at least 35kg on a stable antiretroviral regimen, with no history of treatment failure and no known or suspected resistance to either cabotegravir or rilpivirine. The regimen…

The Guardian - UK

LV=’s on board with £511,000 bonus for boss despite shambles of failed sale

Mark Hartigan has been given £511,000 bonus for 2021 – a humbler CEO would have let the dust settle

Al Jazeera

US regulators approve 2nd COVID booster for those aged 50 and up

US has seen a small uptick in new COVID-19 cases over the past week, raising concern that infections could surge again.

Benzinga

FDA Authorizes Fourth Dose Of Moderna, Pfizer/BioNTech COVID-19 Vaccines For Older People

The FDA has approved a second round of the Moderna Inc (NASDAQ:

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Moderna, BioNTech Pop After FDA OKs Another Covid Booster Round — But Not For Everyone

Vaccine stocks jumped Tuesday after the FDA authorized another round of Covid booster shots for people age 50 and older.

Investors Business Daily

Stock Market Gains As Consumer Confidence Rises; Techs Rise; Vaccine Stocks Pop

The stock market gained as consumer confidence rose, peace talks resumed between Russia and Ukraine and vaccine stocks popped.

The Guardian - US

US FDA approves second Covid booster for Americans 50 and older

Immunocompromised people also eligible for second booster, with CDC now to decide how and when such doses are offered

Tribune News Service

FDA clears way for millions to get additional COVID-19 boosters

U.S. regulators cleared second booster doses of COVID-19 vaccine from Moderna Inc. and the partnership of Pfizer Inc. and BioNTech SE for adults 50 and older, making millions more people eligible for the shots as concern grows about a potential new wave of infections.

Tribune News Service

FDA clears way for millions to get additional COVID-19 boosters

Chicago Sun-Times

FDA approves another COVID booster for 50 and up

The Food and Drug Administration’s decision opens a fourth dose of the Pfizer or Moderna vaccines to those people at least four months after their previous booster.

The Independent UK

FDA approves another Pfizer, Moderna Covid booster for 50 and up

US regulators are allowing people 50 and older to get another booster dose of the Pfizer or Moderna Covid-19 vaccine

1 … 61 62 63 64

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.